probucol has been researched along with Stroke in 9 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "We examined the effect of probucol, a lipid-lowering agent with strong antioxidant properties, on neurological events and survival in stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.70 | Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats. ( Fujimura, A; Kawaguchi, A; Kitoh, Y; Miyashita, F; Sugimoto, K; Tsutsumi, H, 2000) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| " The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage-Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of cilostazol, probucol, or both on IMT in patients with stroke." | 5.24 | Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study. ( Kim, YJ; Kwon, SU; Lee, J; Seo, WK, 2017) |
| " This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function." | 5.22 | Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. ( Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH, 2016) |
| "We examined the effect of probucol, a lipid-lowering agent with strong antioxidant properties, on neurological events and survival in stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.70 | Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats. ( Fujimura, A; Kawaguchi, A; Kitoh, Y; Miyashita, F; Sugimoto, K; Tsutsumi, H, 2000) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| "Probucol is a potent antioxidant and reduces tendon xanthomas in familial hypercholesterolemia patients despite reduction of high-density lipoprotein (HDL)-cholesterol (HDL-C)." | 3.01 | Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). ( Arai, H; Bujo, H; Doi, Y; Fukushima, M; Ishibashi, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Nakagawa, S; Ohama, T; Saito, Y; Tanabe, K; Yamashiro, K; Yamashita, S; Yanagi, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Yamashita, S | 2 |
| Arai, H | 1 |
| Bujo, H | 1 |
| Masuda, D | 2 |
| Ohama, T | 1 |
| Ishibashi, T | 1 |
| Yanagi, K | 1 |
| Doi, Y | 1 |
| Nakagawa, S | 1 |
| Yamashiro, K | 1 |
| Tanabe, K | 1 |
| Kita, T | 1 |
| Matsuzaki, M | 1 |
| Saito, Y | 1 |
| Fukushima, M | 1 |
| Matsuzawa, Y | 2 |
| Hirata, KI | 1 |
| Seo, WK | 2 |
| Kim, YJ | 2 |
| Lee, J | 3 |
| Kwon, SU | 3 |
| Fu, N | 1 |
| Yang, S | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Liang, M | 1 |
| Cong, H | 1 |
| Lin, W | 1 |
| Tian, F | 1 |
| Lu, C | 1 |
| Kim, BJ | 1 |
| Lee, EJ | 1 |
| Park, JH | 1 |
| Hong, KS | 2 |
| Wong, LKS | 1 |
| Yu, S | 1 |
| Hwang, YH | 1 |
| Lee, JS | 2 |
| Rha, JH | 1 |
| Heo, SH | 1 |
| Ahn, SH | 1 |
| Park, JM | 1 |
| Lee, JH | 1 |
| Kwon, JH | 1 |
| Sohn, SI | 1 |
| Jung, JM | 1 |
| Navarro, JC | 1 |
| Kang, DW | 1 |
| Yu, KH | 1 |
| Oh, MS | 1 |
| Miyashita, F | 1 |
| Kawaguchi, A | 1 |
| Sugimoto, K | 1 |
| Kitoh, Y | 1 |
| Tsutsumi, H | 1 |
| Fujimura, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Stroke
| Article | Year |
|---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
5 trials available for probucol and Stroke
| Article | Year |
|---|---|
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
Topics: Aged; Anticholesteremic Agents; Antioxidants; Biological Transport; Cardiovascular Diseases; Carotid | 2021 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Inti | 2017 |
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Topics: Aged; Antioxidants; Combined Modality Therapy; Contrast Media; Coronary Disease; Creatinine; Cystati | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorder | 2016 |
3 other studies available for probucol and Stroke
| Article | Year |
|---|---|
New Horizons for Probucol, an Old, Mysterious Drug.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Tria | 2021 |
New Evidence of Probucol on Cardiovascular Events.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Dyslipidem | 2021 |
Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Body Weight; Hypertension; Male; Probucol; Rats; | 2000 |